CanSense is a company focused on innovation in cancer diagnostics. They develop simple, accurate, and non-invasive cancer detection methods.

CanSense

At CanSense we utilise cutting-edge data analytics and machine learning to maximise the performance of our blood test aimed at triaging patients at high risk of cancer.

A great achievment for the CanSense Team. 

Early detection of cancer in a safe and secure environment for all. Well done Software team. 

#EarlyDetectionofCancer #earlydetectionofbowelcancer #CyberSecurityPlus #CanSense

"We work to accelerate the adoption of new technologies so that we can identify the innovations that are going to have a big impact for our patients and citizens of Wales" - Gareth Healey

And CanSense is doing just that. Their blood tests for simple detection are making diagnoses of bowel cancer quicker and more cost effective. 

We're so proud to be a part of their journey.

Find out more about the cancer projects we're supporting, including CanSense, here: https://lnkd.in/eitxcgDX 

Dean Harris Adam Bryant NIHR (National Institute for Health and Care Research) Swansea Bay University Health Board Cancer Research Wales Health and Care Research Wales Swansea University #CancerInnovation #BowelCancer #Cancer #Innovation #Wales #LiquidBiopsy #Collaboration

Last week, CanSense achieved our Cyber Essentials Plus certification! 🎉 

Cybersecurity is one of the pillars of our company and we are committed to keeping information safe and secure. 

Over the past few months we've been making practical changes to our IT management and working practices to reduce our vulnerability to the most common types of cyber attack.

In addition to improving our practices and security posture, the certification is another step towards being able to use our test to improve early detection of bowel cancer.

Many thanks to Southern IT Networks Ltd and the NCSC's Funder Cyber Essentials Programme ( https://lnkd.in/eNRh2jar) for their support in taking the steps towards certification.

#CanSense #CyberSecurity #CyberEssentialsPlus

"By showcasing innovations like QuicDNA and CanSense, we aim to inspire and show how innovative technologies can transform cancer detection and treatment."

Life Sciences Hub Wales launches series of digital case studies.

Read more: https://lnkd.in/ek99VVqp

#MedTech #Wales #CaseStudies

Missed our recent event with The Academy of Medical Sciences on early detection and diagnosis of cancer? Here’s a snippet of the day. 🎥✨

The event was filled with insightful discussions and innovative ideas that are driving forward cancer care in Wales. 

Keep an eye out for more videos and insights from the first event in this series coming soon!

Join us on our journey to transform cancer diagnosis and treatment. Keep your eyes peeled for an announcement about the next event in this series coming soon 👀

Naomi Joyce Colette Buckley Leanne Price All Wales Medical Genomics Service Cwm Taf Morgannwg University Health Board Peter Bannister Jason Lintern Lewis Egal CanSense Adam Bryant Macmillan Cancer Support

#CancerInnovation #EarlyDetection #CancerDiagnosis #HealthcareInnovation #LifeSciences #Wales #Cancer #CancerCare

'CanSense is developing a simple blood test to detect bowel cancer at its earliest stages.'

Working alongside Life Sciences Hub Wales to demonstrate how we and other Welsh businesses are reshaping cancer detection is truly rewarding, especially in a nation where 60% of bowel cancer cases are diagnosed at a late stage. 

Together, we're striving to save more lives, improve the diagnostic journey, and provide a more inclusive, less invasive approach to screening.

#BowelCancer #EarlyCancerDetection #CanSense #LifeScienceHubWales #LSHW

Clinical trials play such an important role in developing new treatment pathways within the healthcare industry. With continuous advancements happening behind the scenes, it is both empowering and reassuring to witness the ongoing efforts to enhance cancer treatment and overall healthcare standards.

With our own trials forecasted for the near future, we hope to see continuous improvements and discoveries to benefit the cancer diagnostic journey.

https://lnkd.in/eQtY2V-3

#CanSense #BowelCancer #EarlyDetectionOfCancer #ClinicalTrials

“The shame or embarrassment people may feel at the prospect of having their stool tested is not comparable to the feeling of knowing that my mum will never meet my child and become a grandma."  

We recognise that shame and embarrassment play a huge role in the reasons for many cases of late diagnosis when bowel cancer is concerned. 

While we encourage everyone to become familiar with the symptoms and for those over 50 to take advantage of the free FIT test provided to them. CanSense is working on offering a non-invasive, alternative method to traditional bowel cancer screening; aiming to eliminate the associated stigma in hope to increase public uptake by providing a standard-like blood test, a liquid biopsy.

To read more - https://lnkd.in/eh5xP85F

#CanSense #BowelCancer #EarlyDetectionOfBowelCancer #CancerScreening  #LiquidBiopsy

‘The development of a new blood test for the early detection of bowel cancer, which we hope to see incorporated into the Welsh NHS within the next three years’ 

Thrilled to have a mention in the Cancer Research Wales 2024-2029 Research Strategy. 

With sponsored sporting events and hosting lab tours and presentations- it is always an honour to be associated with such a passionate and charitable organisation.  

Additionally, the funding they have provided for academic trials over the past decade has helped launch CanSense on our journey towards early cancer detection.  

CanSense look forward to continuing our relationship with Cancer Research Wales and feel empowered for the future of cancer research – ‘Increasing cancer survival in Wales now and for future generations.’ 

https://lnkd.in/edceXSR9 

#CanSense #CancerResearchWales #BowelCancer #EarlyDetectionOfBowelCancer

Meet the team! - Cerys Mitchell (Jenkins)

In 2014, Cerys began her PhD developing the underlying technology for CanSense, and from there she helped set up the business alongside our other 3 co-founders; Dr Adam Bryant, Prof Peter Dunstan, and Prof Dean Harris. Alongside this, Cerys fulfils the role of our Chief Data Scientist.

Before CanSense, Cerys did post-doc research in spectroscopy and machine learning, performed contract research on medical health records for new pharmaceutical technology and led a team developing software for big health data analytics. 

Her favourite part of CanSense is the people and witnessing what we have and continue to accomplish together as a team. 

Cerys has always put so much passion and effort into her work. Though beyond this, she loves being outside, walking Tash – her geriatric golden retriever, playing golf or paddle boarding. However, since we live in Swansea, which isn't always ideal for outdoor activities, she also likes to sew, especially making dungarees. 

#CanSense #WorkTeam #BowelCancer #EarlyDetectionOfCancer #EarlyDetectionOfBowelCancer #HealthCareInnovations

Metric
Company Name	CanSense
Symbol
MSH ID	COM:CANSENSELTD
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Medical Diagnostics
Country	UK
Stage
Employee Count
Website	cansenseltd.com
LinkedIn	cansense
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CANS

COM:CANSENSELTD

CanSense

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue